Login to Your Account



Deals And M&A NEWS

SHANGHAI – An unlikely union has been forged between San Francisco-based Unity Biotechnology Inc. and Ascentage Pharma Group, of Shanghai.

Aytu Bioscience Inc. CEO Josh Disbrow said that confusion over what endpoints might be acceptable to the FDA in trials with therapies for low testosterone "is a bit of an anomaly, and frankly we view it to some degree as a barrier to entry that's relatively unique."

CEO Sean McCarthy told BioWorld Today that Cytomx Therapeutics Inc.'s deals will be "increasingly strategic," structured for purposes of "not just bringing cash in the door," and the latest with Abbvie Inc. typifies what he's talking about.

More Deals And M&A Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: